A bill to amend title XI of the Social Security Act and title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits.
Drug Price Transparency Act of 2023
This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws.
Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line